Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis

Psychoneuroendocrinology

Volumn 62, Issue , 2015, Pages 18-26

  Carvalho, André F ^a   Köhler, Cristiano A ^b   McIntyre, Roger S ^c   Knöchel, Christian ^d   Brunoni, André R ^e   Thase, Michael E ^f   Quevedo, João ^g,h   Fernandes, Brisa S ^i,j   Berk, Michael ^i,k  

^a Federal University of Ceará   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

ⁱ DEAKIN UNIVERSITY   (Australia)

^j FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Biomarker; Depression; Major depressive disorder; Meta analysis; Neuronal plasticity; Vascular endothelial growth factor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL DERIVED NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

AGE DISTRIBUTION; BODY MASS; COMPARATIVE STUDY; DATA EXTRACTION; DEGREE OF HETEROGENEITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EFFECT SIZE; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; META REGRESSION ANALYSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; PARAMETERS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PUBLISHING; QUALITY CONTROL; REGRESSION ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW; BLOOD; DEPRESSIVE DISORDER; META ANALYSIS;

BIOMARKERS; DEPRESSIVE DISORDER; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947447282     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.07.002     Document Type: Review

References (53)

1. Berent D., Macander M., Szemraj J., Orzechowska A., Galecki P. Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins. Acta Neurobiol. Exp. 2014, 74:82-90.
2. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., Giovannini C., Rillosi L., Ventriglia M., Riva M.A., Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry: Off. J. World Feder. Soc. Biol. Psychiatry 2010, 11:763-773.
3. Brunoni A.R., Baeken C., Machado-Vieira R., Gattaz W.F., Vanderhasselt M.A. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J. Biol. Psychiatry: Off. J. World Feder. Soc. Biol. Psychiatry 2014, 15:411-418.
4. Brunoni A.R., Baeken C., Machado-Vieira R., Gattaz W.F., Vanderhasselt M.A. BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysis. World J. Biol. Psychiatry: Off. J. World Feder. Soc. Biol. Psychiatry 2015, 16:114-122.
5. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol./off. Sci. J. Collegi. Int. Neuropsychopharmacol. (CINP) 2008, 11:1169-1180.
6. Carvalho L., Torre J., Papadopoulos A., Poon L., Juruena M., Markopoulou K., Cleare A., Pariante C. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord. 2013, 148:136-140.
7. Carvalho L.A., Bergink V., Sumaski L., Wijkhuijs J., Hoogendijk W.J., Birkenhager T.K., Drexhage H.A. Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. Transl. Psychiatry 2014, 4:e344.
8. Clark-Raymond A., Halaris A. VEGF and depression: a comprehensive assessment of clinical data. J. Psychiatric Res. 2013, 47:1080-1087.
9. Clark-Raymond A., Meresh E., Hoppensteadt D., Fareed J., Sinacore J., Halaris A. Vascular endothelial growth factor: a potential diagnostic biomarker for major depression. J. Psychiatry Res. 2014, 59:22-27.
10. Davis J., Maes M., Andreazza A., McGrath J.J., Tye S.J., Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol. Psychiatry 2015, 20:152-153.
11. De Winter R.J., Klomp M. Understanding the role of endothelial progenitor cells in cardiovascular disease coronary artery lesion progression, and in-stent restenosis. JACC. Cardiovasc. Interv. 2010, 3:87-89.
12. Dome P., Teleki Z., Rihmer Z., Peter L., Dobos J., Kenessey I., Tovari J., Timar J., Paku S., Kovacs G., Dome B. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol. Psychiatry 2009, 14:523-531.
13. Du M.Y., Wu Q.Z., Yue Q., Li J., Liao Y., Kuang W.H., Huang X.Q., Chan R.C., Mechelli A., Gong Q.Y. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36:11-16.
14. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
15. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
16. Egger M., Smith G.D. Bias in location and selection of studies. BMJ (Clin. Res. ed.) 1998, 316:61-66.
17. Elfving B., Buttenschon H.N., Foldager L., Poulsen P.H., Grynderup M.B., Hansen A.M., Kolstad H.A., Kaerlev L., Mikkelsen S., Borglum A.D., Wegener G., Mors O. Depression and BMI influences the serum vascular endothelial growth factor level. Int. J. Neuropsychopharmacol./Off. Sci. J. Colleg. Int. Neuropsychopharmacol. (CINP) 2014, 17:1409-1417.
18. Elfving B., Plougmann P.H., Wegener G. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci. Lett. 2010, 474:13-16.
19. Fernandes B.S., Gama C.S., Kauer-Sant'Anna M., Lobato M.I., Belmonte-de-Abreu P., Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J. Psychiatry Res. 2009, 43:1200-1204.
20. Fornaro M., Rocchi G., Escelsior A., Contini P., Ghio M., Colicchio S., De Berardis D., Amore M., Fornaro P., Martino M. VEGF plasma level variations in duloxetine-treated patients with major depression. J. Affect. Disord. 2013, 151:590-595.
21. Fournier N.M., Duman R.S. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav. Brain Res. 2012, 227:440-449.
22. Galecki P., Galecka E., Maes M., Orzechowska A., Berent D., Talarowska M., Bobinska K., Lewinski A., Bienkiewicz M., Szemraj J. Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:117-124.
23. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34:2459-2468.
24. Gunsilius E., Petzer A., Stockhammer G., Nussbaumer W., Schumacher P., Clausen J., Gastl G. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000, 58:169-174.
25. Hamilton M. Assessment of change in psychiatric state by means of rating scales. Proc. Roy. Soc. Med. 1966, 59(Suppl):10-13.
26. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
27. Iga J., Ueno S., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., Nakataki M., Song H., Hokoishi K., Tanabe H., Sano A., Ohmori T. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:658-663.
28. Ioannidis J.P. Interpretation of tests of heterogeneity and bias in meta-analysis. J. Eval. Clin. Pract. 2008, 14:951-957.
29. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11946-11950.
30. Kahl K.G., Bens S., Ziegler K., Rudolf S., Kordon A., Dibbelt L., Schweiger U. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34:353-357.
31. Konarski J.Z., McIntyre R.S., Kennedy S.H., Rafi-Tari S., Soczynska J.K., Ketter T.A. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 2008, 10:1-37.
32. Kotan Z., Sarandol E., Kirhan E., Ozkaya G., Kirli S. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther. Adv. Psychopharmacol. 2012, 2:65-74.
33. Lee B.H., Kim Y.K. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J. Affect. Disord. 2012, 136:181-184.
34. Lin P.Y., Tseng P.T. Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a meta-analytic study. J. Psychiatry Res. 2015, 63:20-27.
35. Minelli A., Zanardini R., Abate M., Bortolomasi M., Gennarelli M., Bocchio-Chiavetto L. Vascular endothelial growth factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1322-1325.
36. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269. w264.
37. Molendijk M.L., Spinhoven P., Polak M., Bus B.A., Penninx B.W., Elzinga B.M. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry 2014, 19:791-800.
38. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 2013, 18:595-606.
39. Nowacka M.M., Obuchowicz E. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 2012, 46:1-10.
40. Okamoto Y., Nagai T., Nakajo I., Seta K., Gotoh Y., Fujita N., Fukui T., Masuzawa T. Determination of age-related changes in human vascular endothelial growth factor in the serum and urine of healthy subjects. Clin. Lab. 2008, 54:173-177.
41. Palmer T.D., Willhoite A.R., Gage F.H. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 2000, 425:479-494.
42. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat. Med. 2007, 26:4544-4562.
43. Schweiger U., Greggersen W., Rudolf S., Pusch M., Menzel T., Winn S., Hassfurth J., Fassbinder E., Kahl K.G., Oltmanns K.M., Hohagen F., Peters A. Disturbed glucose disposal in patients with major depression; application of the glucose clamp technique. Psychosom. Med. 2008, 70:170-176.
44. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
45. Simmonds M.C., Higgins J.P. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat. Med. 2007, 26:2982-2999.
46. Smith N.R., Wedge S.R., Pommier A., Barry S.T. Mechanisms that influence tumour response to VEGF-pathway inhibitors. Biochem. Soc. Trans. 2014, 42:1601-1607.
47. Takebayashi M., Hashimoto R., Hisaoka K., Tsuchioka M., Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J. Neural Transm. (Vienna, Austria: 1996) 2010, 117:1119-1122.
48. Taliaz D., Loya A., Gersner R., Haramati S., Chen A., Zangen A. Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. J. Neurosci.: Off. J. Soc. Neurosci. 2011, 31:4475-4483.
49. Ventriglia M., Zanardini R., Pedrini L., Placentino A., Nielsen M.G., Gennarelli M., Bocchio-Chiavetto L. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:146-149.
50. Wang Y.P., Gorenstein C. Psychometric properties of the beck depression inventory-II: a comprehensive review. Rev. Bras. Psiquiatr. (Sao Paulo, Brazil: 1999) 2013, 35:416-431.
51. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4647-4652.
52. Wells, G.A., Shea, B., O'Connel, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2014. The New Castle Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. <> (accessed 23.10.14.). http://www.ohri.ca.
53. Zhao Y.J., Du M.Y., Huang X.Q., Lui S., Chen Z.Q., Liu J., Luo Y., Wang X.L., Kemp G.J., Gong Q.Y. Brain grey matter abnormalities in medication-free patients with major depressive disorder: a meta-analysis. Psychol. Med. 2014, 44:2927-2937.